Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Carol Gurski"'
Autor:
David T. Miyamoto, Shyamala Maheswaran, Jonathan G. Goldin, Richard T. Lee, Philip J. Saylor, Daniel A. Haber, Carol Gurski, Wanling Xie, M. Dror Michaelson, S. Michael Rothenberg, Malgorzata E. Smas, Matthew R. Smith
Publikováno v:
Clinical Cancer Research. 19:3088-3094
Background: Cabozantinib is an oral MET/VEGFR2 inhibitor. A recent phase II study of cabozantinib (100 mg daily) showed improved bone scans in subjects with metastatic castration-resistant prostate cancer (mCRPC), but adverse events (AE) caused frequ
Autor:
Donald S. Kaufman, S. Z. Michaelson, William Oh, Matthew R. Smith, Meredith M. Regan, Kara M. Olivier, Philip W. Kantoff, M. Dror Michaelson, Carol Gurski, B. Spicer
Publikováno v:
Annals of Oncology. 20:913-920
Background This study explored the efficacy and tolerability of sunitinib, an inhibitor of tyrosine kinase receptors, in men with castration-resistant prostate cancer (CRPC). Methods Men with no prior chemotherapy (group A) and men with docetaxel (Ta
Autor:
Donald S. Kaufman, William U. Shipley, Esther Oliva, Nathanael Pinheiro, Allen M. Gown, Niall M. Heney, Gladell P. Paner, Beverly Spicer, Mahul B. Amin, Carol Gurski
Publikováno v:
Human pathology. 44(5)
Muscle invasive urothelial carcinoma has been treated with cystectomy ± adjuvant therapy. Recently, a bladder-sparing protocol has been offered to selected patients closely followed with surveillance biopsies. In this setting, radiation-induced chan
Autor:
Philip J. Saylor, Richard T. Lee, Matthew R. Smith, M. Dror Michaelson, Shyamala Maheswaran, Carol Gurski, Stephen M. Rothenberg, David T. Miyamoto, Daniel A. Haber, Jonathan G. Goldin
Publikováno v:
Journal of Clinical Oncology. 30:4566-4566
4566 Background: Cabo (XL184) is an oral inhibitor of MET and VEGFR2. In a randomized discontinuation trial of cabo 100mg daily, 76% of men with CRPC and bone metastases had partial or complete resolution of bone scan lesions as early as week (wk) 6.
Autor:
Richard B. Lee, Jonathan G. Goldin, Matthew R. Smith, Philip J. Saylor, M. Dror Michaelson, Carol Gurski
Publikováno v:
Molecular Cancer Therapeutics. 10:A90-A90
Background: Cabozantinib is an orally available inhibitor of MET and VEGFR2. In a randomized discontinuation trial of cabozantinib (100 mg daily), 86% of men with mCRPC and bone metastases had partial or complete resolution of lesions on bone scan as